Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
暂无分享,去创建一个
[1] V. Meininger,et al. The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis , 2010, Neurotoxicity Research.
[2] M. Cohen,et al. [Depression in multiple sclerosis]. , 2009, Revue neurologique.
[3] O. Hayaishi,et al. Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide. , 2008, Ciba Foundation symposium.
[4] C. García-Girón,et al. Effect of 3-hydroxyanthranilic acid in the immunosuppressive molecules indoleamine dioxygenase and HLA-G in macrophages. , 2008, Immunology letters.
[5] Gilles J Guillemin,et al. Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.
[6] B. Brew,et al. Effect of quinolinic acid on gene expression in human astrocytes: Implications for Alzheimer's disease , 2007 .
[7] B. Brew,et al. Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques , 2007 .
[8] A. Chiarugi,et al. Kynurenic acid actions in brain and periphery , 2007 .
[9] B. Brew,et al. Characterization of the kynurenine pathway in human oligodendrocytes , 2007 .
[10] G. M. Mackay,et al. Altered kynurenine metabolism correlates with infarct volume in stroke , 2007, The European journal of neuroscience.
[11] V. Karanikas,et al. Tumor immune escape mediated by indoleamine 2,3-dioxygenase. , 2007, Immunology letters.
[12] G. Prendergast,et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.
[13] L. Jermiin,et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. , 2007, Gene.
[14] H. Steinbusch,et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. , 2007, Journal of affective disorders.
[15] János Kálmán,et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease , 2007, Neurochemistry International.
[16] M. Gisslén,et al. Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid , 2007, Brain, Behavior, and Immunity.
[17] Adeeba Kamarulzaman,et al. AIDS Res Hum Retroviruses , 2006 .
[18] T. Stone,et al. KYNURENINE PATHWAY METABOLISM IN PATIENTS WITH OSTEOPOROSIS AFTER 2 YEARS OF DRUG TREATMENT , 2006, Clinical and experimental pharmacology & physiology.
[19] D. Nutt,et al. Tryptophan metabolism in the central nervous system: medical implications , 2006, Expert Reviews in Molecular Medicine.
[20] R. Schwarcz,et al. Kynurenine Pathway Enzymes in Dendritic Cells Initiate Tolerogenesis in the Absence of Functional IDO1 , 2006, The Journal of Immunology.
[21] D. Fuchs,et al. Tryptophan degradation increases with stage in patients with rheumatoid arthritis , 2006, Clinical Rheumatology.
[22] R. Scheyer,et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses , 2006, Neurology.
[23] R. Rosenthal,et al. Differential effects of the tryptophan metabolite3‐hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines , 2006, European journal of immunology.
[24] T. Stone,et al. Tryptophan metabolism and oxidative stress in patients with chronic brain injury , 2006, European journal of neurology.
[25] V. Meininger,et al. Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis , 2006, Neurodegenerative Diseases.
[26] K. Blennow,et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia , 2005, Schizophrenia Research.
[27] O. Takikawa. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. , 2005, Biochemical and biophysical research communications.
[28] Michael Platten,et al. Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite , 2005, Science.
[29] D. Scheuner,et al. ER stress‐regulated translation increases tolerance to extreme hypoxia and promotes tumor growth , 2005, The EMBO journal.
[30] F. Tarantini,et al. Kynurenic Acid Inhibits the Release of the Neurotrophic Fibroblast Growth Factor (FGF)-1 and Enhances Proliferation of Glia Cells, in vitro , 2005, Cellular and Molecular Neurobiology.
[31] G. Smythe,et al. Prolonged Survival of a Murine Model of Cerebral Malaria by Kynurenine Pathway Inhibition , 2005, Infection and Immunity.
[32] B. Brew,et al. Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.
[33] D. Fuchs,et al. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. , 2005, Cancer letters.
[34] F. Moroni,et al. Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus , 2005, Neuropharmacology.
[35] T. Stone,et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease , 2005, Journal of neurochemistry.
[36] R. Schwarcz,et al. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum , 2005, Journal of neurochemistry.
[37] B. Baban,et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.
[38] F. Barkhof,et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS , 2005, Neurology.
[39] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.
[40] K. Tracey,et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis , 2004, Nature Medicine.
[41] G. Hedlund,et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats , 2004, Journal of Neuroimmunology.
[42] D. Fuchs,et al. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. , 2004, Clinical biochemistry.
[43] L. Bruijn,et al. Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.
[44] B. Brew,et al. A&bgr;1-42 induces production of quinolinic acid by human macrophages and microglia , 2003, Neuroreport.
[45] T. Taylor,et al. Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. , 2003, The Journal of infectious diseases.
[46] D. Fuchs,et al. Immune activation and degradation of tryptophan in coronary heart disease , 2003, European journal of clinical investigation.
[47] W. Turski,et al. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis , 2003, Acta neurologica Scandinavica.
[48] Peter A. Ward,et al. Novel strategies for the treatment of sepsis , 2003, Nature Medicine.
[49] D. Fuchs,et al. Longitudinal study of tryptophan degradation during and after pregnancy. , 2003, Life sciences.
[50] D. Munn,et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division , 2002, Immunology.
[51] S. Pastorino,et al. Antagonistic effect of picolinic acid and interferon-γ on macrophage inflammatory protein-1α/β production , 2002 .
[52] G. Giovannoni,et al. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients , 2002, Neuroscience Letters.
[53] U. Grohmann,et al. T cell apoptosis by tryptophan catabolism , 2002, Cell Death and Differentiation.
[54] W. Riedel,et al. Tryptophan, mood, and cognitive function , 2002, Brain, Behavior, and Immunity.
[55] D. Fuchs,et al. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. , 2002, Clinical immunology.
[56] G. Hedlund,et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.
[57] G. Damonte,et al. Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase , 2002, The Journal of experimental medicine.
[58] Gerhard Opelz,et al. Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic Cells , 2002, The Journal of experimental medicine.
[59] B. Brew,et al. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease , 2002, Redox report : communications in free radical research.
[60] T. Stone,et al. The pharmacological manipulation of glutamate receptors and neuroprotection. , 2002, European journal of pharmacology.
[61] C. Harmer,et al. Acute administration of citalopram facilitates memory consolidation in healthy volunteers , 2002, Psychopharmacology.
[62] D. Fuchs,et al. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer , 2002, British Journal of Cancer.
[63] B. Winblad,et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue , 2002, Neuropharmacology.
[64] J. Farrar,et al. The clinical significance of cerebrospinal fluid levels of kynurenine pathway metabolites and lactate in severe malaria. , 2002, The Journal of infectious diseases.
[65] D. Fuchs,et al. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease , 2002, Journal of Neural Transmission.
[66] K. Blennow,et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia , 2001, Neuroscience Letters.
[67] P. Hamilton,et al. Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. , 2001, Anticancer research.
[68] M. Pericak-Vance,et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis , 2001, Nature Genetics.
[69] R. Schwarcz,et al. Increased cortical kynurenate content in schizophrenia , 2001, Biological Psychiatry.
[70] R. Schwarcz,et al. The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.
[71] L. Ellerby,et al. Coupling Endoplasmic Reticulum Stress to the Cell Death Program , 2001, The Journal of Biological Chemistry.
[72] B. Brew,et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.
[73] M. Seishima,et al. Lipopolysaccharide induction of indoleamine 2,3‐dioxygenase is mediated dominantly by an IFN‐γ‐independent mechanism , 2001, European journal of immunology.
[74] M. Murray,et al. Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. , 2001, Nutrition.
[75] M. Raiteri,et al. Presynaptic kynurenate‐sensitive receptors inhibit glutamate release , 2001, The European journal of neuroscience.
[76] D. Fuchs,et al. Neopterin production and tryptophan degradation in humans infected by Streptococcus pyogenes , 2001, Medical Microbiology and Immunology.
[77] L. Massacesi,et al. Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis , 2001, Neuroscience.
[78] B. Dubois,et al. Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy , 2001, AIDS.
[79] M. Altfeld,et al. Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease. , 2000, AIDS research and human retroviruses.
[80] L. Chylack,et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. , 2000, Biochemistry.
[81] B. Brew,et al. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis , 2000, Redox report : communications in free radical research.
[82] G. Melillo,et al. The Tryptophan Catabolite Picolinic Acid Selectively Induces the Chemokines Macrophage Inflammatory Protein-1α and -1β in Macrophages1 , 2000, The Journal of Immunology.
[83] R. Schwarcz,et al. Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. , 2000, European journal of pharmacology.
[84] R. Appelberg,et al. Macrophage Control of Mycobacterial Growth Induced by Picolinic Acid Is Dependent on Host Cell Apoptosis1 , 2000, The Journal of Immunology.
[85] D. Munn,et al. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? , 1999, Immunology today.
[86] A. Chiarugi,et al. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl) thiazol-2yl]-benzenesulfonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase , 1999, Neuropharmacology.
[87] F. Moroni,et al. Kynurenine Hydroxylase Inhibitors Reduce Ischemic Brain Damage: Studies with (m-Nitrobenzoyl)-Alanine (mNBA) and 3,4-Dimethoxy-[-N-4-(Nitrophenyl)Thiazol-2YL]-Benzenesulfonamide (Ro 61-8048) in Models of Focal or Global Brain Ischemia , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[88] D. Munn,et al. Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.
[89] M. Takemura,et al. Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes. , 1998, Archives of biochemistry and biophysics.
[90] H. Gendelman,et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. , 1998, The Journal of infectious diseases.
[91] D. Munn,et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.
[92] A. Lackner,et al. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[93] R. Beninger,et al. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid , 1998, British journal of pharmacology.
[94] M. Gompels,et al. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. , 1998, Clinical chemistry.
[95] F. Leblhuber,et al. Activated Immune System in Patients with Huntington's Disease , 1998, Clinical Chemistry and Laboratory Medicine.
[96] N. Yoshimura,et al. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo , 1997, British journal of pharmacology.
[97] E. Major,et al. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. , 1997, The Biochemical journal.
[98] J. Moffett,et al. Quinolinate Immunoreactivity in Experimental Rat Brain Tumors Is Present in Macrophages but Not in Astrocytes , 1997, Experimental Neurology.
[99] J. Tenu,et al. Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. , 1997, Archives of biochemistry and biophysics.
[100] R. Schwarcz,et al. Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo. , 1997, European journal of pharmacology.
[101] R. Schwarcz,et al. Facilitated brain uptake of 4‐chlorokynurenine and conversion to 7‐chlorokynurenic acid , 1996, Neuroreport.
[102] S. Steinberg,et al. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[103] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[104] A. Saah,et al. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. , 1996, American journal of epidemiology.
[105] J. Moffett,et al. Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis , 1996, AIDS.
[106] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.
[107] S. Schiff,et al. Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children , 1995, Journal of the Neurological Sciences.
[108] P. Morand,et al. Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound (*) , 1995, The Journal of Biological Chemistry.
[109] A. Chiarugi,et al. Comparison of the Neurochemical and Behavioral Effects Resulting from the Inhibition of Kynurenine Hydroxylase and/or Kynureninase , 1995, Journal of neurochemistry.
[110] M. Demitrack,et al. Cerebrospinal fluid levels of kynurenine pathway metabolites in patients with eating disorders: Relation to clinical and biochemical variable , 1995, Biological Psychiatry.
[111] K. Orita,et al. Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin. , 1995, Immunological investigations.
[112] O. H. Viveros,et al. Neurotoxin Quinolinic Acid Is Selectively Elevated in Spinal Cords of Rats with Experimental Allergic Encephalomyelitis , 1995, Journal of neurochemistry.
[113] G. Reynolds,et al. Increased Concentrations of the Neurotoxin 3‐Hydroxykynurenine in the Frontal Cortex of HIV‐1‐Positive Patients , 1995, Journal of neurochemistry.
[114] H. Meltzer,et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response , 1994, Psychiatry Research.
[115] D. Fuchs,et al. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. , 1994, AIDS research and human retroviruses.
[116] R. Beninger,et al. Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: Evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry , 1994, Neuroscience.
[117] A. B. Orlikov,et al. Kynurenine in blood plasma and DST in patients with endogenous anxiety and endogenous depression , 1994, Biological Psychiatry.
[118] G. Lombardi,et al. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities , 1994, Neuroscience.
[119] G. Melillo,et al. Regulation of nitric-oxide synthase mRNA expression by interferon-gamma and picolinic acid. , 1994, The Journal of biological chemistry.
[120] G. Costantino,et al. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. , 1994, Journal of medicinal chemistry.
[121] O. Devinsky,et al. Kynurenine Pathway Metabolites in Cerebrospinal Fluid and Serum in Complex Partial Seizures , 1994, Epilepsia.
[122] R. Beninger,et al. Picolinic acid modulates kainic acid-evoked glutamate release from the striatum in vitro , 1993, Brain Research.
[123] F. Bistoni,et al. Protective effect of picolinic acid on mice intracerebrally infected with lethal doses of Candida albicans , 1993, Antimicrobial Agents and Chemotherapy.
[124] J. Moffett,et al. Antibodies to quinolinic acid reveal localization in select immune cells rather than neurons or astroglia , 1993, Brain Research.
[125] T. Stone,et al. Neuropharmacology of quinolinic and kynurenic acids. , 1993, Pharmacological reviews.
[126] I. Hertz-Picciotto,et al. A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men. , 1993, Journal of acquired immune deficiency syndromes.
[127] A. Koda,et al. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. , 1993, Japanese journal of pharmacology.
[128] P. Wood,et al. Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: In vivo characterization , 1993, Neuropharmacology.
[129] R. Beninger,et al. Action of picolinic acid and structurally related pyridine carboxylic acids on quinolinic acid-induced cortical cholinergic damage , 1992, Brain Research.
[130] G. Lombardi,et al. Nicotinylalanine Increases the Formation of Kynurenic Acid in the Brain and Antagonizes Convulsions , 1992, Journal of neurochemistry.
[131] M. Demitrack,et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.
[132] G. Reynolds,et al. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease , 1992, Neuroscience Letters.
[133] E. Major,et al. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. , 1992, The Biochemical journal.
[134] M. Brodie,et al. Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. , 1992, General Pharmacology.
[135] Elsdon Storey,et al. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex , 1992, Journal of the Neurological Sciences.
[136] A. Grace. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.
[137] L. Varesio,et al. IL-4 inhibits the costimulatory activity of IL-2 or picolinic acid but not of lipopolysaccharide on IFN-gamma-treated macrophages. , 1991, Journal of immunology.
[138] R. S. Smith. The macrophage theory of depression. , 1991, Medical hypotheses.
[139] E. Werner,et al. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. , 1991, Immunology letters.
[140] F. Ceci,et al. Increased plasma free tryptophan levels in human cancer: a tumor related effect? , 1991, Anticancer research.
[141] S. Baig,et al. High performance liquid chromatography as a tool in the definition of abnormalities in monoamine and tryptophan metabolites in cerebrospinal fluid from patients with neurological disorders. , 1991, Biomedical chromatography : BMC.
[142] J. Sidtis,et al. Quinolinic acid in cerebrospinal fluid and serum in HIV‐1 Infection: Relationship to clinical and neurological status , 1991, Annals of neurology.
[143] D. Radzioch,et al. Picolinic acid, a catabolite of tryptophan, as the second signal in the activation of IFN-gamma-primed macrophages. , 1990, Journal of immunology.
[144] S. Gupta,et al. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. , 1990, The Journal of biological chemistry.
[145] R. Beninger,et al. Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites , 1990, Brain Research.
[146] M. Beal,et al. Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid , 1990, Journal of neurochemistry.
[147] W. Katon,et al. Depression and chronic medical illness. , 1990, The Journal of clinical psychiatry.
[148] H. Monyer,et al. 7‐Chlorokynurenate Blocks NMDA Receptor‐Mediated Neurotoxicity in Murine Cortical Culture , 1990, The European journal of neuroscience.
[149] R. Stocker,et al. Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[150] A. Foster,et al. Protection Against N‐methyl‐D‐aspartate Receptor‐Mediated Neuronal Degeneration In Rat Brain by 7‐chlorokynurenate and 3‐amino‐1‐hydroxypyrrolid‐2‐one, Antagonists at The Allosteric Site for Glycine , 1990, The European journal of neuroscience.
[151] G. Norkrans,et al. Indole amine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection , 1989, Journal of neuroscience research.
[152] E. Werner,et al. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. , 1989, Biochimica et biophysica acta.
[153] R. Schwarcz,et al. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system , 1989, Neuroscience Letters.
[154] G. Lombardi,et al. Presence of Kynurenic Acid in the Mammalian Brain , 1988, Journal of neurochemistry.
[155] E. Werner,et al. Tryptophan degradation in patients infected by human immunodeficiency virus. , 1988, Biological chemistry Hoppe-Seyler.
[156] D. Choi,et al. Quinolinate neurotoxicity in cortical cell culture , 1987, Neuroscience.
[157] O. Hayaishi,et al. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[158] W. Pardridge,et al. Neutral amino acid transport at the human blood-brain barrier. , 1986, Federation proceedings.
[159] B. Beutler,et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.
[160] M. Salter,et al. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. , 1985, The Biochemical journal.
[161] E. Pfefferkorn. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[162] M. Cuénod,et al. Identification of quinolinic acid in rat and human brain tissue , 1983, Neuroscience Letters.
[163] R. Schwarcz,et al. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.
[164] T. Stone,et al. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid , 1982, Brain Research.
[165] T. Stone,et al. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. , 1981, European journal of pharmacology.
[166] G. S. Johnson,et al. Control of growth by picolinic acid: differential response of normal and transformed cells. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[167] C. Pierce,et al. Development of primary M, G, and A anti-TNP plaque-forming cell responses in vitro. , 1973, Journal of immunology.
[168] R. McMenamy. Binding of indole analogues to human serum albumin. Effects of fatty acids. , 1965, The Journal of biological chemistry.
[169] B. Brew,et al. Involvement of quinolinic acid in aids dementia complex , 2009, Neurotoxicity Research.
[170] W J Riedel,et al. Serotonin and human cognitive performance. , 2006, Current pharmaceutical design.
[171] S. Gauthier,et al. Studies on kynurenine in human cerebrospinal fluid: Lowered levels in epilepsy , 2005, Journal of Neural Transmission.
[172] R. Beninger,et al. Role of zinc in blockade of excitotoxic action of quinolinic acid by picolinic acid , 2005, Amino Acids.
[173] M. Maes,et al. IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity , 2005, Molecular Psychiatry.
[174] B. Brew,et al. Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.
[175] D. Fuchs,et al. Weight loss in patients with hematological neoplasias is associated with immune system stimulation , 2004, The clinical investigator.
[176] Weimin Hu,et al. Augmented inhibition of Candida albicans growth by murine neutrophils in the presence of a tryptophan metabolite, picolinic acid , 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[177] U. Grohmann,et al. T cell apoptosis by kynurenines. , 2003, Advances in experimental medicine and biology.
[178] B. Brew,et al. Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.
[179] S. Pastorino,et al. Antagonistic effect of picolinic acid and interferon-gamma on macrophage inflammatory protein-1alpha/beta production. , 2002, Cellular immunology.
[180] R. Schwarcz,et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[181] S. Erhardt,et al. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons , 2001, Amino Acids.
[182] 森田 敏子. 3-Hydroxyanthranilic acid,an L-tryptophan metabolite,induces apoptosis in monocyte-derived cells stimulated by interferon-γ , 2001 .
[183] H. Scharfman,et al. Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro , 2000, Amino Acids.
[184] H. Budka,et al. Kynurenic acid metabolism in the brain of HIV-1 infected patients , 2000, Journal of Neural Transmission.
[185] D. Fuchs,et al. Tryptophan degradation and immune activation in Alzheimer's disease , 2000, Journal of Neural Transmission.
[186] G. Melillo,et al. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and -1 beta in macrophages. , 2000, Journal of immunology.
[187] W. Riedel,et al. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation , 1999, Psychopharmacology.
[188] C. Broder,et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. , 1996, Science.
[189] J. Corbeil,et al. Quinolinic acid production is related to macrophage tropic isolates of HIV-1. , 1995, Journal of neurovirology.
[190] E. Borden,et al. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. , 1991, Advances in experimental medicine and biology.
[191] C. Nathan,et al. Role of nitric oxide synthesis in macrophage antimicrobial activity. , 1991, Current opinion in immunology.
[192] D. Rubinow,et al. Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. , 1989, Annals of neurology.
[193] L. Varesio,et al. Antiproliferative activity of picolinic acid due to macrophage activation. , 1987, Drugs under experimental and clinical research.